Miconazole%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520vaginal%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520pessary

## Miconazole Vaginal Pessary ### Overview Miconazole is an imidazole antifungal agent. The vaginal pessary formulation is intended for localized treatment of vaginal yeast infections. ### Primary Indications Vulvovaginal candidiasis (yeast infection). ### Adult Dosing * **100 mg pessary:** Insert one pessary vaginally at bedtime for 7 days. * **200 mg pessary:** Insert one pessary vaginally at bedtime for 3 days. * **High strength 1200 mg pessary:** Insert one pessary vaginally as a single dose. ### Pediatric Dosing Safety and efficacy in pediatric patients younger than 12 years have not been established. Use in this age group is generally not recommended unless directed by a healthcare provider. ### Dose Adjustments No dose adjustments are typically required based on renal or hepatic impairment, as systemic absorption is minimal. ### Contraindications * Hypersensitivity to miconazole or any component of the formulation. * Use with oral or topical sirolimus, everolimus, or other sensitive CYP3A4 substrates (due to potential for increased drug levels). ### Adverse Effects Common adverse effects may include vulvovaginal burning, itching, or irritation. Pelvic cramping may also occur. ### Key Drug Interactions Miconazole can inhibit CYP3A4 and CYP2C9 enzymes, potentially increasing the plasma concentrations of other drugs metabolized by these enzymes. This is particularly relevant for oral antifungals and certain immunosuppressants or anticoagulants. However, systemic absorption from the vaginal pessary is generally low, which may limit the clinical significance of these interactions. Caution is advised if co-administered with sensitive CYP3A4 substrates. ### Monitoring * Monitor for relief of symptoms (itching, burning, discharge). * Assess for any signs of local irritation or allergic reaction. ### Clinical Pearls * The pessary should be inserted as high into the vagina as possible. * Treatment should be completed even if symptoms improve sooner. * Avoid intercourse during treatment as the medication can reduce the effectiveness of latex condoms and diaphragms. * If symptoms do not improve after completing the course of treatment, or if they worsen, consult a healthcare provider. --- **Disclaimer:** This information is intended for educational purposes only and does not constitute medical advice. Always verify current prescribing information and consult with a qualified healthcare professional before making any decisions related to patient care.